Real-world experience with vimseltinib for tenosynovial giant cell tumor

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry will collect medical record data and patient-reported outcomes from people with TGCT who are prescribed vimseltinib without changing their care. Eligible participants must have a confirmed TGCT diagnosis and either plan to start vimseltinib or have begun it within the past six months; those who received other systemic TGCT therapies in the six months before starting vimseltinib or who are enrolled in an interventional vimseltinib trial are excluded. Data captured will include treatment patterns, dosing and timing, adverse events, and health-related quality of life measures. The sponsor is Deciphera Pharmaceuticals and enrollment is conducted at a Synexus Clinical Research site in Wilmington, North Carolina.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Diagnosis of TGCT according to medical records
2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated.
3. Has provided informed consent and medical records release

Exclusion Criteria:

1\. Participant is active in an interventional clinical trial of vimseltinib

Where it's running

• Synexus Clinical Research, US INC
  Wilmington, North Carolina, United States Recruiting

Study contacts

• Study coordinator: Clinical Team
• Email: clinicaltrials@deciphera.com
• Phone: 888-724-3274

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vimseltinib’s effect on P-glycoprotein inhibition in healthy men

  This study tests whether vimseltinib changes how a P-glycoprotein substrate (dabigatran) behaves in the body of healthy men.

  Recruiting Phase 1 Deciphera Pharmaceuticals, LLC · Overland Park, Kansas · NCT07744802

• Pimicotinib for Japanese people with tenosynovial giant cell tumor (J-MANEUVER)

  This trial will test whether pimicotinib is safe, reaches effective blood levels, and improves symptoms in Japanese participants with unresectable tenosynovial giant cell tumor.

  Recruiting at 4 sites Phase 2 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Chūōku and 3 other locations · NCT07499362

• Indocyanine green fluorescence imaging to visualize tenosynovial giant cell tumor during surgery.

  This will test whether injecting indocyanine green helps surgeons see tumor tissue under near-infrared imaging in people having surgery for tenosynovial giant cell tumor.

  Recruiting Phase 4 Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Shanghai · NCT07315841

• Evaluating Vimseltinib for Chronic Graft-Versus-Host Disease in Adults

  This study is testing if a new medication called vimseltinib can help adults with tough cases of chronic graft-versus-host disease feel better after other treatments haven't worked.

  Recruiting at 26 sites Phase 2 Deciphera Pharmaceuticals, LLC · Duarte, California and 25 other locations · NCT06619561

• Assessing the safety and tolerability of ABSK-021 in patients with advanced solid tumors

  This study is testing a new oral medication called ABSK-021 to see if it's safe and tolerable for people with advanced solid tumors, especially those with tenosynovial giant cell tumor, who haven't had success with other treatments.

  Recruiting at 3 sites Phase 1 Abbisko Therapeutics Co, Ltd · Beverly Hills, California and 16 other locations · NCT04192344

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.